International Journal of Cardiovascular ResearchISSN: 2324-8602

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

In vitro Hemocompatibility Testing of Dyneema Purity® Fibers Patch and Clinically Used Cardiovascular Prostheses

Currently available materials for vascular- and heart valve prostheses carry drawbacks, including the requirement of strong anticoagulants, moderate durability, and the inapplicability for endovascular treatment. Dyneema Purity® fibers are made from ultra-high molecular weight polyethylene, are very thin, strong, flexible and resistant to fatigue and abrasion. This material might be attractive for use in vascular- and valvular surgery. In this study the hemocompatibility of yarn-composed patches of Dyneema Purity® fibers was assessed.
Three methods were used to compare the hemocompatibility of yarn-composed patches of Dyneema Purity® fibers with 5 clinically used yarn-composed and
membrane-based patches. First, patches were perfused with human blood in a perfusion chamber, thereafter adhered red blood cells and platelets were assessed by scanning electron microscopy. Second, the platelet activation caused by patches was tested using fluorescence-activated cell sorting assay at 1, 3, 6, 24, and 48 hours. Third, various coagulation parameters activated by patches were measured using enzyme-linked immunosorbent assay.
Perfusion experiment showed no differences between patches of Dyneema Purity® fibers and control patches for single platelet and red blood cell adherence. Less platelet aggregation was visible on Dyneema Purity®, compared with one yarn-composed patch, and aggregates were equal compared with the other 4 controls. The platelet activation experiment showed no differences for Dyneema Purity® and other yarn-composed patches. Compared with membranebased patches, there was more platelet activation at 1 hour and 24 hours, but no significant difference at 48 hours. The coagulation activation experiment showed comparable coagulation activation on all patches.
Patches of Dyneema Purity® fibers are noninferior to the used control patches in terms of red blood cell- and platelet adhesion and platelet- and coagulation activation. Therefore, this material may be attractive for use in cardiovascular applications.

Special Features

Full Text


Track Your Manuscript

Media Partners